| Added by | mollevi |
|---|---|
| Group name | EquipeCG |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: IRCM, Institut de Recherche en Cancerologie de Montpellier, Montpellier, F-34298, France. INSERM, U1194, Montpellier F-34298, France. Universite Montpellier, Montpellier F-34298, France. Institut regional du Cancer Montpellier, Montpellier F-34298, France. Department of Medical Oncology, Hospital del Mar, Barcelona 08003, Spain. Department of Surgery and Cancer, Imperial Centre for Translational and Experimental Medicine (ICTEM), Imperial College London, Hammersmith Hospital Campus, London W12 0NN, UK. alt-title: British journal of cancer accession-num: 27685445 |
| Tags | _EndnoteXML import |
| Date Added | 2018/07/20 - 10:05:58 |
| Date Modified | 2018/07/20 - 10:05:58 |
| Parent item | FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer |
Institut de Recherche en Cancérologie de
